瑞舒伐他汀钙片对冠心病合并心力衰竭患者的治疗效果  

Therapeutic effect of rosuvastatin calcium tablets on patients with coronary heart disease and heart failure

作　　者：潘朦朦 杨东妮[1] 刘欣卉 PAN Meng-meng;YANG Dong-ni;LIU Xin-hui(Internal Medicine-Cardiovascular Department,Shenyang Red Cross Hospital,Shenyang 110000,China)

机构地区：[1]沈阳市红十字会医院心内科,110000 [2]辽宁中医药大学,110000

出　　处：《中国实用医药》2021年第2期116-118,共3页China Practical Medicine

摘　　要：目的探讨瑞舒伐他汀钙片对冠心病合并心力衰竭患者的血脂指标、心功能与炎症因子水平的影响。方法80例冠心病合并心力衰竭患者,依据药物治疗方案不同分为对照组和实验组,每组40例。对照组接受基础药物方案治疗,实验组在对照组治疗基础上给予瑞舒伐他汀钙片治疗。比较两组患者治疗前后的血脂[总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]水平、心功能指标[左室舒张末期内径(LVEDD)、左心室射血分数(LVEF)、左室收末缩期内径(LVESD)]以及炎症因子[超敏C反应蛋白(hs-CRP)、肿瘤坏死因子α(TNF-α)、脑钠肽(BNP)]水平。结果治疗后,实验组患者TC(4.74±0.55)mmol/L、TG(1.23±0.21)mmol/L、HDL-C(3.98±0.55)mmol/L均明显低于对照组的(5.97±0.84)、(1.86±0.42)、(5.02±0.46)mmol/L,LDL-C(1.83±0.33)mmol/L高于对照组的(1.33±0.26)mmol/L;实验组患者LVEDD(50.53±4.66)mm、LVEF(56.62±4.67)%、LVESD(37.28±3.24)mm均优于对照组的(59.23±6.72)mm、(49.23±5.01)%、(40.28±3.08)mm;实验组患者Hs-CRP(6.31±0.53)mg/L、TNF-α(153.23±12.12)ng/L、BNP(557.34±36.45)μg/L均低于对照组的(8.82±0.55)mg/L、(287.32±21.21)ng/L、(892.53±42.44)μg/L。差异均具有统计学意义(P<0.05)。结论冠心病合并心力衰竭患者接受瑞舒伐他汀钙片治疗,有助于其血脂指标、心功能和炎症因子的调节,因而应用价值较高。Objective To discuss the effect of rosuvastatin calcium tablets on blood lipid index,cardiac function and inflammatory factors of patients with coronary heart disease and heart failure.Methods A total of 80 patients with coronary heart disease and heart failure were divided into control group and experimental group according to different medications,with 40 cases in each group.The control group received basic drug treatment,and the experimental group received rosuvastatin calcium tablets on the basis of the control group.The blood lipid[total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C)]levels,heart function indicators[left ventricular end diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),left ventricular end systolic diameter(LVESD)]and inflammatory factor[high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α),brain natriuretic peptide(BNP)]levels before and after treatment were compared between the two groups.Results After treatment,TC(4.74±0.55)mmol/L,TG(1.23±0.21)mmol/L and HDL-C(3.98±0.55)mmol/L of the experimental group were obviously lower than(5.97±0.84),(1.86±0.42)and(5.02±0.46)mmol/L of the control group,and LDL-C(1.83±0.33)mmol/L was higher than(1.33±0.26)mmol/L of the control group;LVEDD(50.53±4.66)mm,LVEF(56.62±4.67)%and LVESD(37.28±3.24)mm of the experimental group were better than(59.23±6.72)mm,(49.23±5.01)%and(40.28±3.08)mm of the control group;hs-CRP(6.31±0.53)mg/L,TNF-α(153.23±12.12)ng/L and BNP(557.34±36.45)μg/L of the experimental group were lower than(8.82±0.55)mg/L,(287.32±21.21)ng/L and(892.53±42.44)μg/L of the control group.The difference was statistically significant(P<0.05).Conclusion Rosuvastatin calcium tablets is helpful to the regulation of blood lipid index,cardiac function and inflammatory factors of patients with coronary heart disease complicated with heart failure,so it has high practical value.

关 键 词：瑞舒伐他汀钙片 冠心病 心力衰竭 血脂指标 心功能 炎症因子 

分 类 号：R541.6[医药卫生—心血管疾病] R541.4[医药卫生—内科学]